NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

Dollar change +0.10
Percentage change 0.74	%

Peers: FATE RARE CORT QURE VKTX VSTM PVLA LPTX XERS XBIO

| Held by: VTI IWM VXF IWO XBI IBB VTWO IWC LFSC DFAC

Index	RUT	P/E	-	EPS (ttm)	-3.73	Insider Own	22.49%	Shs Outstand	49.49M	Perf Week	5.47%
Market Cap	681.10M	Forward P/E	-	EPS next Y	-2.97	Insider Trans	2.74%	Shs Float	38.53M	Perf Month	23.53%
Income	-175.87M	PEG	-	EPS next Q	-0.85	Inst Own	89.06%	Short Float	16.12%	Perf Quarter	53.76%
Sales	0.00M	P/S	-	EPS this Y	-3.28%	Inst Trans	20.67%	Short Ratio	10.62	Perf Half Y	16.20%
Book/sh	2.93	P/B	4.67	EPS next Y	16.52%	ROA	-90.20%	Short Interest	6.21M	Perf Year	20.70%
Cash/sh	5.09	P/C	2.69	EPS next 5Y	20.85%	ROE	-150.50%	52W Range	7.30 - 15.50	Perf YTD	61.75%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-20.06%	ROI	-70.24%	52W High	-11.61%	Beta	0.05
Dividend TTM	-	Quick Ratio	10.44	Sales past 5Y	-25.00%	Gross Margin	-	52W Low	87.67%	ATR (14)	0.74
Dividend Ex-Date	-	Current Ratio	10.44	EPS Y/Y TTM	-18.75%	Oper. Margin	-	RSI (14)	68.17	Volatility	5.24% 7.88%
Employees	150	Debt/Eq	0.74	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	26.33
Option/Short	Yes / Yes	LT Debt/Eq	0.73	EPS Q/Q	-10.23%	Payout	-	Rel Volume	0.67	Prev Close	13.60
Sales Surprise	-	EPS Surprise	-6.24%	Sales Q/Q	-	Earnings	Mar 12 BMO	Avg Volume	584.97K	Price	13.70
SMA20	12.82%	SMA50	15.44%	SMA200	23.60%	Trades		Volume	376,709	Change	0.74%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-31-25	Initiated	JMP Securities	Mkt Outperform	$19
Jan-07-25	Initiated	TD Cowen	Buy	$30
Dec-18-24	Initiated	BofA Securities	Buy	$22
Jun-15-20	Initiated	H.C. Wainwright	Buy	$30
Jul-29-19	Initiated	SVB Leerink	Outperform	$31
Mar-20-19	Initiated	Needham	Buy	$35
Oct-30-18	Initiated	Jefferies	Buy	$30
Sep-21-18	Initiated	Cantor Fitzgerald	Overweight
Aug-31-17	Initiated	BTIG Research	Buy	$18

Today 07:00AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-30-25 07:00AM	KalVista Pharmaceuticals to Present at the Citizens Life Sciences Conference (Business Wire) +5.28%
Apr-12-25 12:42AM	KalVista: Poised For Rare Disease Transformation (Seeking Alpha)
Apr-08-25 10:27AM	KalVista licenses commercialisation rights for HAE to Kaken in Japan (Pharmaceutical Technology) -10.26%
06:30AM	KalVista Pharmaceuticals Enters Into Licensing Agreement With Kaken Pharmaceutical to Commercialize Sebetralstat for HAE in Japan (Business Wire)
07:00AM	Loading…
Apr-02-25 07:00AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-31-25 07:00AM	KalVista Pharmaceuticals to Present at 24th Annual Needham Virtual Healthcare Conference (Business Wire)
Mar-26-25 11:14AM	KalVista Pharmaceuticals enrols all subjects in hereditary angioedema drug trial (Clinical Trials Arena)
Mar-25-25 07:00AM	KalVista Pharmaceuticals Announces Early Completion of Enrollment in KONFIDENT-KID Pediatric HAE Trial (Business Wire)
Mar-12-25 07:00AM	KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update (Business Wire)
Mar-10-25 07:00AM	KalVista Pharmaceuticals to Host Investor Webcast Highlighting Commercialization Strategy, Plans and Progress for Sebetralstat in Hereditary Angioedema (Business Wire)
Mar-04-25 07:00AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-03-25 07:00AM	KalVista Pharmaceuticals Shares Latest Sebetralstat Findings at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting (Business Wire)
Feb-24-25 07:00AM	KalVista Pharmaceuticals to Present at Upcoming Investor Conferences (Business Wire)
Feb-21-25 07:00AM	KalVista Pharmaceuticals to Present New Sebetralstat Data at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting (Business Wire) -5.73%
07:00AM	Loading…
Feb-10-25 07:00AM	KalVista Pharmaceuticals Presents New Sebetralstat Data at the Western Society of Allergy, Asthma & Immunology 2025 Annual Meeting (Business Wire)
Feb-04-25 07:00AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +5.75%
Jan-21-25 07:00AM	KalVista Announces Orphan Drug Designation and NDA Submission for Sebetralstat in Japan for Hereditary Angioedema (Business Wire) +5.42%
Jan-08-25 06:30AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.94%
Dec-16-24 07:00AM	KalVista Appoints Jeb Ledell as Chief Operating Officer (Business Wire)
Dec-05-24 06:30AM	KalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational Update (Business Wire)
Dec-04-24 06:30AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-26-24 07:00AM	KalVista Pharmaceuticals Appoints Laurence Reid, Ph.D., to Board of Directors (Business Wire)
Nov-12-24 06:30AM	KalVista Pharmaceuticals to Present at Upcoming Investor Conferences (Business Wire)
Nov-05-24 07:29AM	KalVista Secures $184M Financing for Sebetralstat Launch (TipRanks)
06:30AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-04-24 07:05AM	KalVista Pharmaceuticals Announces Pricing of a $55 Million Underwritten Offering of Common Stock and Concurrent Private Placement of $5 Million (Business Wire) +9.61%
07:00AM	KalVista Pharmaceuticals Enters into Non-Dilutive Synthetic Royalty Financing with DRI Healthcare Trust (Business Wire)
Oct-28-24 06:30AM	KalVista Pharmaceuticals Presents New Sebetralstat Data at the 2024 American College of Allergy Asthma and Immunology (Business Wire)
Oct-18-24 06:30AM	KalVista Pharmaceuticals to Present Data at the 2024 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) (Business Wire)
12:29PM	Loading…
Oct-04-24 12:29PM	KalVista Pharmaceuticals Presents Sebetralstat Data at the 2024 HAEi Global Angioedema Forum (Business Wire)
Oct-02-24 06:30AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-30-24 06:30AM	KalVista Announces the Submission of Additional Marketing Authorization Applications for Sebetralstat for the Oral On-Demand Treatment of Hereditary Angioedema (Business Wire) -6.16%
Sep-26-24 06:30AM	KalVista Pharmaceuticals Announces Nine Abstracts Accepted for Presentation at the HAEi Global Angioedema Forum (GAF) (Business Wire) +5.71%
Sep-10-24 07:00AM	KalVista Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference (Business Wire) -5.56%
06:30AM	KalVista Appoints Brian Piekos as Chief Financial Officer (Business Wire)
Sep-06-24 06:30AM	KalVista Pharmaceuticals Presents Sebetralstat Data at Bradykinin Symposium 2024 (Business Wire)
Sep-05-24 06:30AM	KalVista Pharmaceuticals Reports First Fiscal Quarter Results and Provides Operational Update (Business Wire)
Sep-04-24 06:30AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-03-24 06:30AM	KalVista Announces FDA Acceptance of New Drug Application for Sebetralstat for Oral On-Demand Treatment of Hereditary Angioedema (Business Wire) -7.62%
Aug-29-24 06:30AM	KalVista Pharmaceuticals Announces Six Abstracts Accepted for Presentation at the 2024 Bradykinin Symposium (Business Wire)
Aug-15-24 06:30AM	KalVista Announces Validation of Marketing Authorization Application by the European Medicines Agency for Sebetralstat for Hereditary Angioedema (Business Wire)
Aug-02-24 06:30AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-11-24 02:52PM	KALV Stock Earnings: KalVista Pharma Misses EPS for Q4 2024 (InvestorPlace)
06:30AM	KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results (Business Wire)
Jul-02-24 06:30AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-27-24 06:30AM	KalVista Initiates KONFIDENT-KID Trial for On-demand Treatment of Hereditary Angioedema Attacks with Sebetralstat in Children Aged 2 to 11 (Business Wire) +6.54%
Jun-18-24 06:30AM	KalVista Submits New Drug Application to FDA for Sebetralstat as First Oral On-demand Treatment for Hereditary Angioedema (Business Wire)
Jun-06-24 06:30AM	KalVista Pharmaceuticals Presents Data at Eastern Allergy Conference 2024 and the Japanese Dermatological Association 2024 (Business Wire)
Jun-04-24 06:30AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-03-24 06:30AM	KalVista Pharmaceuticals Presents Data on Persisting Unmet Needs in Hereditary Angioedema at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024 (Business Wire)
May-31-24 04:09PM	KalVista Pharmaceuticals Announces New England Journal of Medicine Publishes Oral Sebetralstat Phase 3 Data Demonstrating its Potential to Transform the Treatment Landscape for People with Hereditary Angioedema (Business Wire)
May-24-24 06:30AM	KalVista Pharmaceuticals Announces Ten Abstracts Accepted for Presentation at the European Academy of Allergy and Clinical Immunology Congress 2024 (Business Wire)
May-21-24 06:30AM	KalVista Pharmaceuticals to Present at Upcoming Investor Conferences (Business Wire)
May-02-24 06:30AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-01-24 06:30AM	KalVista Pharmaceuticals Highlights Strategic Plans for Coming Fiscal Year (Business Wire) +7.31%
Apr-22-24 06:30AM	KalVista Pharmaceuticals Appoints William C. Fairey to Board of Directors (Business Wire)
Apr-05-24 06:30PM	ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors (Barrons.com)
Apr-03-24 06:30AM	KalVista Pharmaceuticals to Present at 23rd Annual Needham Virtual Healthcare Conference (Business Wire)
Apr-02-24 06:30AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-18-24 06:30AM	KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas (Business Wire)
Mar-12-24 06:30AM	KalVista Pharmaceuticals Awarded UK Promising Innovative Medicine (PIM) Designation for Sebetralstat (Business Wire)
Mar-11-24 06:30AM	KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update (Business Wire) -8.77%
Mar-08-24 06:30AM	KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americas (Business Wire)
Mar-07-24 06:30AM	KalVista Pharmaceuticals Announces Appointment of Benjamin L. Palleiko as Chief Executive Officer (Business Wire)
Mar-06-24 06:30AM	KalVista Pharmaceuticals to Participate in the Leerink Partners 2024 Global Biopharma Conference (Business Wire)
Mar-04-24 06:30AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-27-24 06:30AM	KalVista Pharmaceuticals Presents Data on Unmet Needs in HAE from a Patient Perspective at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting (Business Wire) +6.79%
Feb-26-24 06:30AM	KalVista Pharmaceuticals Presents Additional Phase 3 KONFIDENT Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting (Business Wire) +8.82%
Feb-20-24 06:30AM	KalVista Pharmaceuticals Awarded UK Innovation Passport for Sebetralstat (Business Wire) -7.13%
Feb-16-24 06:30AM	KalVista Pharmaceuticals to Present Phase 3 Sebetralstat Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting (Business Wire)
Feb-15-24 06:30AM	KalVista Pharmaceuticals Announces Pricing of a $160.1 Million Public Offering of Common Stock and Pre-Funded Warrants (Business Wire)
Feb-14-24 04:18PM	KalVista Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (Business Wire)
Feb-13-24 07:10AM	UPDATE 1-KalVista meets main goals in late-stage trial for genetic disease (Reuters) -7.42%
06:40AM	KalVista meets main goals in late-stage trial for skin condition treatment (Reuters)
06:30AM	KalVista Pharmaceuticals Reports Phase 3 KONFIDENT Trial Meets All Endpoints for Sebetralstat as First Oral On-demand Therapy for Hereditary Angioedema (Business Wire)
01:30AM	Kalvista pill succeeds in late-stage study for rare swelling disorder (BioPharma Dive)
Feb-02-24 06:30AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-01-24 12:02PM	Hedge Fund and Insider Trading News: David Einhorn, Crispin Odey, Bill Ackman, Stanley Druckenmiller, Ken Griffin, Burke Herbert Financial Services (BHRB), KalVista Pharmaceuticals, Inc. (KALV), and More (Insider Monkey)
Jan-13-24 03:12AM	Insider Sell: Chief Scientific Officer Edward Feener Sells 22,679 Shares of KalVista ... (GuruFocus.com)
Jan-12-24 03:03AM	Insider Sell: Chief Scientific Officer Edward Feener Sells 17,321 Shares of KalVista ... (GuruFocus.com)
Dec-30-23 09:02AM	Insider Sell: CEO Thomas Crockett Sells 30,000 Shares of KalVista Pharmaceuticals Inc (KALV) (GuruFocus.com)
Dec-29-23 06:45AM	16 Most Promising Long-Term Stocks According to Analysts (Insider Monkey)
Dec-20-23 06:30AM	KalVista Pharmaceuticals Announces Publication of First Oral Factor XIIa Data in Frontiers in Pharmacology (Business Wire)
Dec-07-23 04:49PM	KalVista Pharmaceuticals Inc (KALV) Reports Second Fiscal Quarter Results (GuruFocus.com) -9.03%
06:30AM	KalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational Update (Business Wire)
Dec-05-23 06:30AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-23-23 05:14AM	Insider Sell Alert: CEO Thomas Crockett Offloads Shares of KalVista Pharmaceuticals Inc (GuruFocus.com)
Nov-22-23 05:04AM	Insider Sell Alert: KalVista Pharmaceuticals Inc's Benjamin Palleiko Sells 13,008 Shares (GuruFocus.com)
Nov-14-23 10:31PM	3 Micro-Cap Stocks That Could Be Moonshots (InvestorPlace)
06:30AM	KalVista Pharmaceuticals Presents Real-World Data at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (Business Wire)
Nov-13-23 06:30AM	KalVista Pharmaceuticals Announces Phase 3 KONFIDENT Trial Milestone Achieved (Business Wire)
Nov-07-23 06:30AM	KalVista Pharmaceuticals to Present at Upcoming Investor Conferences (Business Wire)
Nov-03-23 06:30AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-02-23 06:30AM	KalVista Pharmaceuticals to Present Data at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (Business Wire)
Oct-30-23 09:32AM	12 Best Micro Cap Stocks To Invest In (Insider Monkey)
Oct-25-23 09:40AM	Are Medical Stocks Lagging Amneal Pharmaceuticals (AMRX) This Year? (Zacks) -6.71%
Oct-24-23 06:30AM	KalVista Pharmaceuticals Presents Data on HAE Attacks in Patients Receiving Long-Term Prophylaxis at the Asia Pacific Association of Allergy, Asthma and Clinical Immunology 2023 International Conference (Business Wire)
Oct-09-23 09:40AM	Are Medical Stocks Lagging Cabaletta Bio (CABA) This Year? (Zacks)
Oct-03-23 06:30AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)

KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: Sebetralstat for HAE and Factor XIIa. The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello on March 26, 2004 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Venrock Healthcare Capital Par	10% Owner	Apr 09 '25	Buy	9.42	25,000	235,500	5,303,985	Apr 11 05:22 PM
Palleiko Benjamin L	CHIEF EXECUTIVE OFFICER	Mar 07 '25	Sale	11.97	6,669	79,828	287,811	Mar 10 06:43 PM
Audhya Paul K.	CHIEF MEDICAL OFFICER	Feb 24 '25	Sale	10.02	2,394	23,988	102,940	Feb 25 08:37 PM
Yea Christopher	CHIEF DEVELOPMENT OFFICER	Feb 24 '25	Sale	10.02	1,918	19,218	93,952	Feb 25 08:36 PM
Yea Christopher	CHIEF DEVELOPMENT OFFICER	Feb 18 '25	Sale	9.82	2,601	25,553	92,745	Feb 19 08:47 PM
Audhya Paul K.	CHIEF MEDICAL OFFICER	Feb 18 '25	Sale	9.82	3,125	30,701	100,334	Feb 19 08:46 PM
Palleiko Benjamin L	CHIEF EXECUTIVE OFFICER	Feb 18 '25	Sale	9.82	5,104	50,143	278,855	Feb 19 08:46 PM
Venrock Healthcare Capital Par	10% Owner	Feb 12 '25	Buy	9.23	100,000	923,000	5,217,285	Feb 14 07:45 PM
Venrock Healthcare Capital Par	10% Owner	Feb 13 '25	Buy	9.33	61,700	575,661	5,278,985	Feb 14 07:45 PM
Venrock Healthcare Capital Par	10% Owner	Feb 07 '25	Buy	9.29	73,649	684,199	5,086,445	Feb 11 07:51 PM
Venrock Healthcare Capital Par	10% Owner	Feb 11 '25	Buy	9.18	26,703	245,134	5,117,285	Feb 11 07:51 PM
Venrock Healthcare Capital Par	10% Owner	Feb 10 '25	Buy	9.14	4,137	37,812	5,090,582	Feb 11 07:51 PM
Venrock Healthcare Capital Par	10% Owner	Jan 30 '25	Buy	8.76	43,707	382,873	4,986,480	Feb 03 07:42 PM
Venrock Healthcare Capital Par	10% Owner	Feb 03 '25	Buy	9.22	14,562	134,262	5,012,796	Feb 03 07:42 PM
Venrock Healthcare Capital Par	10% Owner	Jan 31 '25	Buy	8.89	11,754	104,493	4,998,234	Feb 03 07:42 PM
Palleiko Benjamin L	CHIEF EXECUTIVE OFFICER	Dec 09 '24	Sale	9.75	7,627	74,363	274,596	Dec 09 09:08 PM
Audhya Paul K.	CHIEF MEDICAL OFFICER	Nov 26 '24	Sale	9.87	2,187	21,586	97,012	Nov 27 08:45 PM
Yea Christopher	CHIEF DEVELOPMENT OFFICER	Nov 26 '24	Sale	9.87	1,963	19,378	91,142	Nov 27 08:43 PM
Palleiko Benjamin L	CHIEF EXECUTIVE OFFICER	Nov 18 '24	Sale	9.26	14,400	133,294	266,598	Nov 19 07:19 PM
Yea Christopher	CHIEF DEVELOPMENT OFFICER	Nov 18 '24	Sale	9.26	7,192	66,573	89,980	Nov 19 07:18 PM
Audhya Paul K.	CHIEF MEDICAL OFFICER	Nov 18 '24	Sale	9.26	8,077	74,766	94,199	Nov 19 07:18 PM
Palleiko Benjamin L	CHIEF EXECUTIVE OFFICER	Sep 09 '24	Sale	12.19	7,352	89,622	250,800	Sep 10 08:31 PM
Audhya Paul K.	CHIEF MEDICAL OFFICER	Aug 23 '24	Sale	12.40	2,135	26,474	83,745	Aug 26 08:00 PM
Yea Christopher	CHIEF DEVELOPMENT OFFICER	Aug 23 '24	Sale	12.40	1,916	23,758	85,676	Aug 26 07:58 PM
Audhya Paul K.	CHIEF MEDICAL OFFICER	Aug 19 '24	Sale	12.01	7,973	95,782	80,880	Aug 21 09:26 PM
Palleiko Benjamin L	CHIEF EXECUTIVE OFFICER	Aug 19 '24	Sale	12.01	14,215	170,769	242,527	Aug 21 09:25 PM
Yea Christopher	CHIEF DEVELOPMENT OFFICER	Aug 19 '24	Sale	12.01	7,102	85,318	84,467	Aug 21 09:25 PM
Palleiko Benjamin L	CHIEF EXECUTIVE OFFICER	Jun 07 '24	Sale	11.53	7,465	86,068	224,547	Jun 10 06:42 PM
Feener Edward P.	CHIEF SCIENTIFIC OFFICER	May 20 '24	Sale	11.76	8,088	95,151	72,858	May 21 05:59 PM
Audhya Paul K.	CHIEF MEDICAL OFFICER	May 20 '24	Sale	11.76	13,175	154,997	70,325	May 21 05:58 PM
Palleiko Benjamin L	CHIEF EXECUTIVE OFFICER	May 20 '24	Sale	11.76	21,959	258,337	216,387	May 21 05:57 PM
Yea Christopher	CHIEF DEVELOPMENT OFFICER	May 20 '24	Sale	11.76	11,610	136,586	80,074	May 21 05:55 PM

Open in Screener

ORKA

Oruka Therapeutics Inc

May 02 • 03:46PM ET

10.78

Dollar change +0.69
Percentage change 6.85	%

Healthcare • Biotechnology • USA • NASD

ORKA Oruka Therapeutics Inc daily Stock Chart

Held by: VTI VXF IBB ITOT IWC IBBQ BIB ISCB

Index	-	P/E	-	EPS (ttm)	-6.43	Insider Own	15.35%	Shs Outstand	37.44M	Perf Week	6.85%
Market Cap	403.66M	Forward P/E	-	EPS next Y	-2.60	Insider Trans	2.18%	Shs Float	31.69M	Perf Month	14.45%
Income	-59.09M	PEG	-	EPS next Q	-0.51	Inst Own	71.92%	Short Float	7.45%	Perf Quarter	-19.84%
Sales	0.00M	P/S	-	EPS this Y	39.17%	Inst Trans	40.72%	Short Ratio	8.30	Perf Half Y	-64.03%
Book/sh	10.13	P/B	1.06	EPS next Y	-10.22%	ROA	-27.24%	Short Interest	2.36M	Perf Year	-52.13%
Cash/sh	10.03	P/C	1.07	EPS next 5Y	16.79%	ROE	-28.19%	52W Range	5.49 - 33.00	Perf YTD	-44.40%
Dividend Est.	-	P/FCF	-	EPS past 5Y	36.88%	ROI	-15.43%	52W High	-67.33%	Beta	-0.40
Dividend TTM	-	Quick Ratio	28.89	Sales past 5Y	0.00%	Gross Margin	-	52W Low	96.56%	ATR (14)	0.90
Dividend Ex-Date	Aug 26, 2024	Current Ratio	28.89	EPS Y/Y TTM	-44.72%	Oper. Margin	-	RSI (14)	58.10	Volatility	7.39% 11.05%
Employees	28	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	39.14
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	28.72%	Payout	-	Rel Volume	0.33	Prev Close	10.09
Sales Surprise	-	EPS Surprise	28.13%	Sales Q/Q	-	Earnings	Mar 06 AMC	Avg Volume	284.65K	Price	10.78
SMA20	18.43%	SMA50	5.92%	SMA200	-42.23%	Trades		Volume	91,038	Change	6.85%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-04-25	Initiated	Wolfe Research	Outperform	$20
Oct-11-24	Initiated	Stifel	Buy	$49
Oct-07-24	Initiated	H.C. Wainwright	Buy	$45
Sep-17-24	Initiated	Leerink Partners	Outperform	$44
Sep-16-24	Initiated	TD Cowen	Buy
Sep-13-24	Initiated	Jefferies	Buy	$40
Feb-27-18	Initiated	Ascendiant Capital Markets	Buy	$2
Oct-09-13	Initiated	Dawson James	Buy	$3.75

Apr-29-25 07:00AM	Oruka Therapeutics to Present at Bank of America Securities 2025 Health Care Conference (GlobeNewswire)
Mar-07-25 08:30AM	Oruka Therapeutics Announces Preclinical Data for ORKA-002 at the 2025 American Academy of Dermatology Annual Meeting (GlobeNewswire)
Mar-06-25 04:09PM	Oruka Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-19-25 07:00AM	Oruka Therapeutics to Present at Multiple March Investor Conferences (GlobeNewswire)
Dec-20-24 07:15AM	Oruka Therapeutics doses first participants in Phase 1 trial of ORKA-001 (TipRanks)
07:00AM	Loading…
Dec-19-24 07:00AM	Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody (GlobeNewswire)
Dec-18-24 07:00AM	Oruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI) (GlobeNewswire)
Nov-19-24 08:00AM	Oruka Therapeutics to Present at Piper Sandler's 36th Annual Healthcare Conference (GlobeNewswire) +5.54%
Nov-13-24 04:25PM	Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -6.43%
Nov-04-24 07:00AM	Oruka Therapeutics to Present at Multiple November Investor Conferences (GlobeNewswire)
Sep-25-24 07:08AM	Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of Dermatology and Venereology Congress (GlobeNewswire)
Sep-12-24 07:05AM	Oruka Therapeutics Announces $200 Million Private Placement (GlobeNewswire) -12.22%
07:00AM	Oruka Therapeutics Announces Accelerated Clinical Timelines and Upcoming Presentation at EADV Supporting ORKA-001's Profile as a Potentially Best-in-Class Half-Life Extended Antibody Targeting IL-23p19 (GlobeNewswire)
Sep-03-24 07:00AM	Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million (GlobeNewswire) -11.46%
Aug-29-24 04:50PM	ARCA biopharma Announces Completion of Merger with Oruka Therapeutics and Implementation of Reverse Stock Split (GlobeNewswire) +33.19%
07:30PM	Loading…
Aug-26-24 07:30PM	ARCA biopharma Provides Update Regarding Special Dividend Amount in Connection with the Proposed Merger with Oruka Therapeutics (GlobeNewswire) -8.41%
Aug-23-24 04:30PM	ARCA biopharma Announces 1-for-12 Reverse Stock Split in Connection with the Proposed Merger with Oruka Therapeutics (GlobeNewswire) +6.12%
Aug-16-24 04:15PM	ARCA biopharma Declares Special Dividend in Connection with the Proposed Merger with Oruka Therapeutics (GlobeNewswire) +21.36%
Aug-01-24 04:15PM	ARCA biopharma Announces Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) +5.07%
Jun-28-24 02:16AM	Why Are Hedge Funds Shorting ARCA Biopharma, Inc. (ABIO)? (Insider Monkey) +6.39%
Jun-26-24 11:08PM	What Is Short Selling In Stock Market? 15 Stocks Hedge Funds are Shorting (Insider Monkey)
May-14-24 01:48PM	3 Short-Squeeze Stocks Ready to Soar on Roaring Kitty Rally (InvestorPlace)
Apr-25-24 09:55PM	ABIO Stock Earnings: ARCA biopharma Reported Results for Q1 2024 (InvestorPlace)
04:15PM	ARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-03-24 02:30PM	Why Is ARCA Biopharma (ABIO) Stock Up 85% Today? (InvestorPlace) +90.06%
12:00PM	Small-Cap ARCA Biopharma Stock Soars On Merger Pact: The Details (Benzinga)
07:30AM	ARCA biopharma and Oruka Therapeutics Announce Merger Agreement (GlobeNewswire)
Feb-01-24 04:35PM	ARCA biopharma Announces 2023 Financial Results (GlobeNewswire)
Oct-18-23 04:25PM	ARCA biopharma Announces Third Quarter 2023 Financial Results (GlobeNewswire)
Jul-21-23 04:25PM	ARCA biopharma Announces Second Quarter 2023 Financial Results (GlobeNewswire)
11:30AM	Loading…
Jul-13-23 11:30AM	We're Not Very Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn Rate (Simply Wall St.)
Apr-24-23 04:25PM	ARCA biopharma Announces First Quarter 2023 Financial Results (GlobeNewswire)
Feb-24-23 04:20PM	ARCA biopharma Announces 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-03-23 10:19AM	Here's Why We're Not Too Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn Situation (Simply Wall St.)
Dec-19-22 04:05PM	James Flynn Joins ARCA biopharma Board of Directors (GlobeNewswire)
Nov-14-22 09:24AM	One ARCA biopharma, Inc. (NASDAQ:ABIO) insider upped their stake by 5,155% in the previous year (Simply Wall St.)
Oct-28-22 04:15PM	ARCA biopharma Announces Third Quarter 2022 Financial Results (GlobeNewswire)
Aug-02-22 04:15PM	ARCA biopharma Announces Second Quarter 2022 Financial Results (GlobeNewswire)
Jul-18-22 06:14AM	Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Jun-21-22 04:05PM	Jacob Ma-Weaver Joins ARCA biopharma Board of Directors (GlobeNewswire) +5.56%
May-05-22 04:15PM	ARCA biopharma Retains Ladenburg Thalmann to Support Strategic Options Review (GlobeNewswire) -5.79%
May-02-22 04:15PM	ARCA biopharma Announces First Quarter 2022 Financial Results (GlobeNewswire)
Apr-18-22 04:30PM	ARCA biopharma Establishes Special Committee of the Board of Directors (GlobeNewswire)
Apr-05-22 01:35AM	Albioma : Governance changes (GlobeNewswire)
Apr-01-22 07:09AM	ARCA biopharma's Tissue Factor Inhibitor Disappoints In Mid-Stage COVID-19 Study (Benzinga)
Mar-31-22 04:15PM	ARCA biopharma Reports Topline Results for ASPEN-COVID-19 Phase 2b Clinical Trial (GlobeNewswire)
Mar-14-22 04:15PM	ARCA biopharma Announces 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-07-22 04:30PM	Battalion Oil Corporation Announces Fourth Quarter and Full Year 2021 Financial and Operating Results (GlobeNewswire)
Feb-08-22 04:21AM	We're Keeping An Eye On ARCA biopharma's (NASDAQ:ABIO) Cash Burn Rate (Simply Wall St.)
Jan-04-22 08:30AM	Data on Gencaro Impact on Prevention of Bradycardia Published in Heart Rhythm O2 (GlobeNewswire)
Dec-02-21 08:30AM	ARCA biopharma Announces Completion of Enrollment in Phase 2b ASPEN-COVID-19 Clinical Trial Evaluating rNAPc2 as a Potential Treatment for Patients Hospitalized with COVID-19 (GlobeNewswire)
Nov-20-21 07:01AM	ClearPoint Neuro (NASDAQ:CLPT) shareholders are still up 635% over 3 years despite pulling back 13% in the past week (Simply Wall St.)
Nov-09-21 04:15PM	ARCA biopharma to Present at the Q4 Virtual Investor Summit on November 17th (GlobeNewswire)
Nov-02-21 04:15PM	ARCA biopharma Announces Third Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-29-21 07:03AM	Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace)
06:26AM	ARCA Biopharma Stock Gains As Safety Committee Recommends COVID-19 Trial To Continue Unchanged (Benzinga)
Oct-28-21 04:30PM	ASPEN-COVID-19 Data and Safety Monitoring Committee Recommends Continuing Phase 2b Clinical Trial to Completion Based on Interim Analysis of Efficacy and Safety Data (GlobeNewswire)
Sep-16-21 08:30AM	ARCA biopharma Announces Enrollment of First International Patient in Phase 2b Clinical Trial Evaluating rNAPc2 as a Potential Treatment for COVID-19 (GlobeNewswire)
Aug-16-21 08:05AM	ARCA biopharma to Present at the Q3 Virtual Investor Summit on August 18th (GlobeNewswire) -5.14%
Aug-12-21 01:15AM	We Think ARCA biopharma (NASDAQ:ABIO) Can Afford To Drive Business Growth (Simply Wall St.)
Aug-09-21 08:00AM	ARCA biopharma Announces Submission of PCT Patent Application for the Treatment of Coronavirus Infection and Associated Coagulopathy with rNAPc2 (GlobeNewswire)
Aug-04-21 04:15PM	ARCA biopharma Announces Second Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire) +5.44%
Jul-28-21 08:00AM	Gencaro Atrial Fibrillation Phase 2B Results Selected for Publication in Circulation: Arrhythmia and Electrophysiology (GlobeNewswire)
Jul-13-21 08:00AM	ARCA biopharma Provides Update on ASPEN-COVID-19 Phase 2b Clinical Trial Evaluating rNAPc2 as a Potential Treatment for COVID-19 (GlobeNewswire) -14.09%
Jul-09-21 08:00AM	ARCA biopharma to Present at Access to Giving Virtual Investor Conference on July 13th (GlobeNewswire) +5.75%
Jul-08-21 11:20AM	50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021 (ACCESSWIRE) -6.95%
Jul-07-21 08:00AM	ARCA biopharma Announces rNAPc2 COVID-19 Patent Assignment Agreement (GlobeNewswire) +9.36%
Jun-23-21 09:35AM	50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021 (ACCESSWIRE)
May-11-21 04:15PM	ARCA biopharma Announces First Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
May-05-21 04:05PM	Christopher Graybill Joins ARCA as Vice President, Clinical Development (GlobeNewswire)
May-03-21 04:30PM	ARCA biopharma Announces C. Jeff Dekker to be Appointed Chief Financial Officer (GlobeNewswire)
Mar-18-21 04:30PM	ARCA biopharma Announces 2020 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-13-21 01:09AM	Here's Why We're Not Too Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn Situation (Simply Wall St.)
Dec-15-20 08:30AM	ARCA biopharma Announces First Patients Enrolled in ASPEN-COVID-19 Phase 2b Clinical Trial Evaluating rNAPc2 (AB201) as a Potential Treatment for COVID-19 (GlobeNewswire)
Dec-09-20 05:40PM	ARCA biopharma Announces Location Change for 2020 Annual Meeting of Stockholders (GlobeNewswire)
Nov-23-20 12:28PM	ARCA Biopharma gets Fast Track designation for experimental COVID-19 treatment (MarketWatch) +7.46%
08:30AM	AB201 Development as a Potential Treatment for COVID-19 Receives U.S. FDA Fast Track Designation (GlobeNewswire)
Nov-02-20 08:30AM	ARCA biopharma Announces Third Quarter 2020 Financial Results and Provides Corporate Update (GlobeNewswire) +5.19%
Oct-07-20 08:30AM	ARCA biopharma Announces FDA Approval of IND Application for AB201 as a Potential Treatment for COVID-19 (GlobeNewswire) -8.49%
Oct-05-20 04:30PM	ARCA biopharma Announces Promotion of Chief Medical Officer and Vice President, Regulatory Affairs & Quality (GlobeNewswire) +12.61%
Sep-21-20 08:00AM	ARCA biopharma Announces Submission of IND Application to U.S. FDA for AB201 as a Potential Treatment for COVID-19 (GlobeNewswire) -10.62%
Aug-17-20 08:49AM	We Think ARCA biopharma (NASDAQ:ABIO) Can Afford To Drive Business Growth (Simply Wall St.)
Aug-12-20 08:00AM	ARCA Biopharma Announces Completion of FDA Pre-IND Consultation Under Coronavirus Treatment Acceleration Program for AB201 as a Potential Treatment for Severe COVID-19 (ACCESSWIRE) -7.51%
Aug-05-20 04:15PM	Arca Biopharma Announces Second Quarter 2020 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-07-20 08:30AM	SARS-CoV-2 Cell Entry Mechanisms in Intact Human Heart Published in JACC: Basic to Translational Science by University of Colorado Anschutz Medical Campus and ARCA biopharma Investigators (GlobeNewswire)
Jun-03-20 09:56AM	ARCA biopharma Announces Closing of $6.1 Million Registered Direct Offering (GlobeNewswire) -5.39%
09:56AM	Biotech Stock Roundup: GILD's Coronavirus Drug Update, NTLA-REGN Deal & More (Zacks)
Jun-01-20 08:20AM	ARCA Biopharma Announces $9.4 Million Registered Direct Offering (GlobeNewswire) -26.98%
May-29-20 12:24PM	A Mighty May: Over $200,000 In Gross Profits (Benzinga) -34.41%
09:59AM	Company News for May 29, 2020 (Zacks)
May-28-20 04:19PM	Arca Biopharma Nearly Quintuples On Plans To Test A Coronavirus Drug (Investor's Business Daily) +386.33%
12:14PM	Arca Biopharma Stock Triples On Plans To Test A Coronavirus Treatment (Investor's Business Daily)
10:27AM	Price Over Earnings Overview: ARCA biopharma (Benzinga)
08:00AM	ARCA biopharma Announces AB201 Development Program for Treatment of COVID-19 Associated Coagulopathy (GlobeNewswire)
May-07-20 08:30AM	Clinical Data Evaluating Gencaro for the Treatment of Atrial Fibrillation in Heart Failure Patients Featured in Three Presentations at the 2020 Heart Rhythm Scientific Sessions (GlobeNewswire)
May-06-20 04:30PM	ARCA Biopharma Announces First Quarter 2020 Financial Results And Provides Corporate Update (GlobeNewswire)
Feb-18-20 04:30PM	ARCA biopharma Announces Fiscal Year 2019 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-01-20 08:31AM	Does Market Volatility Impact ARCA biopharma, Inc.'s (NASDAQ:ABIO) Share Price? (Simply Wall St.)
Nov-06-19 04:10PM	ARCA Biopharma Announces Third Quarter 2019 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-03-19 08:47AM	Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Invest In Growth? (Simply Wall St.)

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Venrock Healthcare Capital Par	10% Owner	Feb 14 '25	Buy	11.44	88,794	1,015,803	4,148,428	Feb 27 06:42 PM
Venrock Healthcare Capital Par	10% Owner	Feb 13 '25	Buy	11.63	14,950	173,868	4,059,634	Feb 27 06:42 PM
Venrock Healthcare Capital Par	10% Owner	Feb 12 '25	Buy	11.86	8,971	106,396	4,044,684	Feb 27 06:42 PM
Venrock Healthcare Capital Par	10% Owner	Feb 11 '25	Buy	10.95	9,593	105,043	4,035,713	Feb 27 06:42 PM
Venrock Healthcare Capital Par	10% Owner	Feb 10 '25	Buy	10.90	574	6,257	4,026,120	Feb 27 06:42 PM
JANUS HENDERSON GROUP PLC	10% Owner	Aug 16 '24	Buy	2.93	5,818	17,067	2,117,213	Aug 20 02:23 PM
JANUS HENDERSON GROUP PLC	10% Owner	Jul 24 '24	Buy	3.20	189,856	606,873	2,081,168	Jul 26 10:50 AM
JANUS HENDERSON GROUP PLC	10% Owner	Jul 25 '24	Buy	3.05	30,227	92,292	2,111,395	Jul 26 10:50 AM
JANUS HENDERSON GROUP PLC	10% Owner	Jul 03 '24	Buy	3.55	166,042	589,565	1,648,577	Jul 12 07:38 PM
JANUS HENDERSON GROUP PLC	10% Owner	Jul 11 '24	Buy	3.45	94,537	326,304	1,891,312	Jul 12 07:38 PM
JANUS HENDERSON GROUP PLC	10% Owner	Jul 10 '24	Buy	3.46	55,463	192,130	1,796,775	Jul 12 07:38 PM
JANUS HENDERSON GROUP PLC	10% Owner	Jul 08 '24	Buy	3.46	47,492	164,190	1,724,395	Jul 12 07:38 PM
JANUS HENDERSON GROUP PLC	10% Owner	Jul 05 '24	Buy	3.43	28,326	97,065	1,676,903	Jul 12 07:38 PM
JANUS HENDERSON GROUP PLC	10% Owner	Jul 09 '24	Buy	3.43	16,917	58,091	1,741,312	Jul 12 07:38 PM

KALV

KalVista Pharmaceuticals Inc

ORKA

Oruka Therapeutics Inc

Upgrade your FINVIZ experience